论文部分内容阅读
HCV is the causative agent of type-C hepatitis, previously known as non-A non-B type, and one of the most resilient viral infections that affects human liver.The high degree of virus variability and the absence of effective vaccines via conventional approaches stimulate much interest in the application of DNA vaccines against HCV.Up to date the reported DNA vaccines are covering almost all the constituting structural and nonstructural HCV proteins.Most of the developed applications included DNA constructs encoding a single gene or several combined gene sequences, administrated with or without adjuvants or other adjuvant-like materials.Different techniques have been applied and evaluated for vaccine delivery which include gene gun, electroporation, microparticles, and liposomes.